Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.45 |
| ▸ | NOS2 | P35228 | 3/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276755 | 0.84 | KCNH2 (0.52) | KCNH2ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL1556910 | 0.81 | BACE1 (0.43) | BACE1NOS2NOS3APPNOS1 | |
| SCHEMBL537491 | 0.79 | KCNH2 (0.44) | NOS2NOS1KCNH2ADORA2AADORA1 | |
| SCHEMBL12934586 | 0.78 | KCNH2 (0.42) | KCNH2ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL13564633 | 0.77 | KCNH2 (0.45) | KCNH2ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL791993 | 0.77 | CCR1 (0.44) | NOS2NOS3KCNH2POLB | |
| SCHEMBL24618108 | 0.76 | HRH1 (0.42) | BACE1NOS2NOS1KCNH2ADORA2A | |
| SCHEMBL29792017 | 0.76 | HRH1 (0.42) | BACE1NOS2NOS1KCNH2ADORA2A | |
| SCHEMBL3534071 | 0.76 | NOS2 (0.38) | BACE1NOS2NOS3APPNOS1 | |
| SCHEMBL2825978 | 0.76 | ALDH1A1 (0.46) | BACE1NOS2NOS3APPNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | claimed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | claimed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | claimed |
| WO-2025151517-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS ASSOCIATED WITH MISSFOLDING OF ALPHA-SYNUCLEIN PROTEIN | WAVEBREAK THERAPEUTICS LIMITED (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| EP-3749305-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Université de Strasbourg (FR) | 2020-12-16 | — | — | EP | disclosed |
| CN-111683660-A | Compounds and compositions for the treatment of pain | 斯特拉斯堡大学 | 2020-09-18 | — | — | CN | disclosed |
| WO-2019149965-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITE DE STRASBOURG (FR) | 2019-08-08 | — | — | WO | disclosed |
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1799647-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037501-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ACHE, TRPV1, OPRL1 | BACE1 3964/4885NOS2 1125/4885NOS3 725/4885 |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD11B2 | BACE1 797/4885NOS2 1087/4885NOS3 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.